<DOC>
	<DOC>NCT01063517</DOC>
	<brief_summary>To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy</brief_summary>
	<brief_title>Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Recurrent or metastatic gastric cancer that has progressed following first linetherapy Confirmed ATM protein status by IHC archival tumour sample At least one lesion (measurable and/or nonmeasurable) that can be accurately assessed by imaging (CT/MRI) at baseline and follow up visits More than one prior chemotherapy regimen for the treatment of gastric cancer in the metastatic or recurrent setting Any previous treatment with a PARP inhibitor, including olaparib Patients with second primary cancer, except; adequately treated non melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for &gt;5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Poly(ADP ribose)</keyword>
	<keyword>polymerase (PARP)</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>olaparib</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>ATM AZD2281</keyword>
	<keyword>Ku0059436</keyword>
	<keyword>Homologous Recombination deficiency (HRD)</keyword>
	<keyword>Recurrent gastric cancer</keyword>
	<keyword>metastatic gastric cancer</keyword>
</DOC>